TY - JOUR T1 - A High Rate of COVID-19 Vaccine Hesitancy Among Arabs: Results of a Large-scale Survey JF - medRxiv DO - 10.1101/2021.03.09.21252764 SP - 2021.03.09.21252764 AU - Eyad A. Qunaibi AU - Mohamed Helmy AU - Iman Basheti AU - Iyad Sultan Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/10/2021.03.09.21252764.abstract N2 - In this study, we present the results of the first large-scale multinational study (36,220 participants) that measures vaccine hesitancy among Arab-speaking subjects. Our analysis shows a significant rate of vaccine hesitancy among Arabs in and outside the Arab region (83% and 81%, respectively). The most cited reasons for hesitancy are concerns about side effects and distrust in healthcare policies, vaccine expedited production, published studies and vaccine producing companies. We also found that female participants, participants 30-59 year-old, those with no chronic diseases, those with lower-level of academic education, and those who do not know the type of vaccine authorized in their countries are more hesitant to receive COVID-19 vaccination. On the other hand, participants who regularly receive the influenza vaccine, health care workers, and those from countries with higher rates of COVID-19 infections showed more vaccination willingness. Interactive representation of our results is posted on our project website at https://mainapp.shinyapps.io/CVHAA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board (IRB) at King Hussein Cancer center (Approval No. 21 KHCC 0.34).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of the project is available through the project's website. https://mainapp.shinyapps.io/CVHAA ER -